Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis

@inproceedings{Overgaard2016Liraglutide3M,
  title={Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis},
  author={Rune Viig Overgaard and Kristin C C Petri and Lisbeth Vesterg{\aa}rd Jacobsen and Christine Bj{\o}rn Jensen},
  booktitle={Clinical pharmacokinetics},
  year={2016}
}
Background and ObjectivesThis analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals.MethodsSamples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials. Dose proportionality of liraglutide in obese… CONTINUE READING
BETA

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

  • The New England journal of medicine
  • 2015
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Obesity and type 2 diabetes: what can be unified and what needs to be individualized?

  • The Journal of clinical endocrinology and metabolism
  • 2011
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…